Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06006117
What this trial is testing

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Who this might be right for
Marginal Zone Lymphoma
The Lymphoma Academic Research Organisation 260
Not applicableApproved For MarketingNCT06064500
What this trial is testing

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer
Amgen
Early research (Phase 1)Study completedNCT04702737
What this trial is testing

AMG 757 in Participants With Neuroendocrine Prostate Cancer

Who this might be right for
Neuroendocrine Prostate Cancer
Amgen 41
Testing effectiveness (Phase 2)Looking for participantsNCT07106710
What this trial is testing

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Institute of Hematology & Blood Diseases Hospital, China 30
Testing effectiveness (Phase 2)Looking for participantsNCT07111520
What this trial is testing

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
BioNTech SE 880
Not applicableLooking for participantsNCT07564219
What this trial is testing

BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)CAR T CellsBispecific Antibodies
Universitätsklinikum Hamburg-Eppendorf 45
Early research (Phase 1)UnknownNCT04303520
What this trial is testing

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

Who this might be right for
CD19-positive ALL
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine 20
Early research (Phase 1)UnknownNCT04887025
What this trial is testing

Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine 25
Testing effectiveness (Phase 2)Looking for participantsNCT06479239
What this trial is testing

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

Who this might be right for
Pancreas CancerPancreatic Cancer
University of Virginia 23
Testing effectiveness (Phase 2)Looking for participantsNCT06529718
What this trial is testing

Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

Who this might be right for
Biliary Tract Cancer
UNICANCER 72
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07743632
What this trial is testing

Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC

Who this might be right for
Breast CancerTriple Negative Breast Cancer
University of Kansas Medical Center 110
Testing effectiveness (Phase 2)Looking for participantsNCT06996132
What this trial is testing

Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma

Who this might be right for
Relapsed or Refractory Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 25
Testing effectiveness (Phase 2)Looking for participantsNCT05523947
What this trial is testing

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

Who this might be right for
HER2-Positive Solid Tumor
Yuhan Corporation 147
Post-approval studies (Phase 4)Not Yet RecruitingNCT07554014
What this trial is testing

A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa

Who this might be right for
Hidradenitis Suppurativa (HS)
Second Affiliated Hospital, Zhejiang University, School of Medicine 50
Early research (Phase 1)Study completedNCT03650348
What this trial is testing

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder Cancer+1 more
Pieris Pharmaceuticals, Inc. 41
Early research (Phase 1)Active Not RecruitingNCT03399799
What this trial is testing

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 279
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07029776
What this trial is testing

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)
University of Arkansas 50
Testing effectiveness (Phase 2)Looking for participantsNCT05882370
What this trial is testing

TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study

Who this might be right for
Hepatocellular Carcinoma
Fei Gao 30
Testing effectiveness (Phase 2)Looking for participantsNCT07079631
What this trial is testing

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
BioNTech SE 482
Very early researchEnded earlyNCT04034446
What this trial is testing

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Who this might be right for
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China 2
Next Page